Tesamorelin

Overview

Tesamorelin is a synthetic research peptide that functions as a growth hormone-releasing hormone (GHRH) analog. It is designed to stimulate the natural production and release of growth hormone in laboratory studies. Tesamorelin is widely researched for its potential impact on fat metabolism, body composition, and growth hormone pathways in preclinical models such as laboratory rodents.

Benefits

Preclinical studies suggest Tesamorelin may support increased growth hormone secretion, improved protein synthesis, and a reduction in visceral adipose tissue in research subjects. Its ability to specifically target abdominal fat makes it a unique tool in studies focused on fat metabolism and body composition management.
Source: Falutz J, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 2010.

Possible Side Effects

In laboratory settings, test subjects given Tesamorelin have demonstrated mild side effects such as injection site irritation, slight water retention, joint discomfort, or temporary changes in blood glucose markers. Effects depend on dose, duration, and species used in the research study.
Source: Falutz J, et al., NEJM, 2010.

Dosage & Administration

Tesamorelin is administered via subcutaneous injection following approved laboratory research protocols. Typical research dosages range from 1 mg to 2 mg per day, depending on the study design and species involved. Administration is usually daily to support consistent monitoring of metabolic markers and body composition changes in test models.
For laboratory research use only. Not for human consumption.

Summary

Tesamorelin is a growth hormone-releasing hormone analog developed exclusively for research investigating growth hormone pathways, visceral fat reduction, and metabolic health in preclinical models. Studies indicate it may help reduce abdominal fat and increase growth hormone secretion, with mild side effects such as injection site redness or fluid retention observed in test subjects. Tesamorelin is typically administered via subcutaneous injection daily, with dosage customized to each study’s requirements and test species.
Strictly for research purposes only. Not for human use.